1073 results
Thumbnail

D2.147 - Comparison of clinical outcomes with Benralizumab in severe eosinophilic asthma: Switched and naïve patients

Thumbnail

D2.149 - EFFECTIVENESS AND SAFETY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY WITH Pru p3 EXTRACT IN PATIENTS WITH LTP ALLERGY

Thumbnail

D2.151 - Study design for A multicenter, open label, randomized Study to inveStigate the effIcacy of Subcutaneous immunoTherapy combined with vitamin D3 in children and adolescent patients with allergic rhinitis (ASSIST study)

Thumbnail

D2.152 - Study design for the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders: a multicenter prospective observational study (CALM study)

Thumbnail

D2.153 - Allergenicity and Immunogenicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus‐Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy

Thumbnail

D2.154 - Real-life observational study on the effectiveness of a broad-spectrum allergen product in unresponsive pediatric patients

Thumbnail

D2.155 - Factors associated with higher serum IgG4 response in children treated with allergen immunotherapy

Thumbnail

D2.156 - Study on the Effect of the Mucosal Vaccine MV130 on Innate Immunity Factors in School-Age Children

Thumbnail

D2.157 - Peanut allergen-loaded microneedle array patch modulates the immune response to peanut allergy in Balb/c and C3H/HeJ mouse model

Thumbnail

D2.158 - Epitope Analysis and Mutation Design in Jug r 1 for Hypoallergenic Walnut Immunotherapy

Thumbnail

D2.162 - Low dose oral immunotherapy for children with severe cow's milk allergy

Thumbnail

D2.163 - Effectiveness and safety of Venom ImmunoTherapy (VIT) with “Rapid Cluster” induction protocol

Thumbnail

D2.164 - Pediatric bee venom allergy: family background matters

Thumbnail

D2.165 - Safety Profile and Clinical Outcome of Sublingual Immunotherapy (SLIT) with Pru p 3 in Patients with LTP Allergy Undergoing Food Reintroduction

Thumbnail

D2.166 - Randomized Controlled Trial of Sublingual Immunotherapy for Egg Allergy

Thumbnail

D2.168 - Systemic reactions to subcutaneous immunotherapy in children

Thumbnail

D2.170 - The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season

Thumbnail

D2.171 - The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment

Thumbnail

D2.172 - Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions

Thumbnail

D2.173 - Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis